Faron Pharmaceuticals Ltd - Turku, Finland-based developer of cancer immunotherapies - Non-Executive Chair Tuomo Patsi buys 21,500 ordinary shares at EUR2.435 per share on Monday for a total of EUR52,353. Brings Patsi's shareholding in Faron to 53,265 shares, with 0.05% of company voting rights. Read More
Faron Pharmaceuticals Ltd - Turku, Finland-based developer of cancer immunotherapies - Appoints Ralph Hughes as chief business officer, effective from next Wednesday. Notes Hughes' prior experience as senior vice president at PharmaVentures, and his extensive experience in commercial due diligence, market access and the business development process. Adds that he will be part of the management team and the business development team. "We are delighted to have such an experienced pharmaceutical market access and strategic commercial development expert to join us as the new CBO", says Chief Executive Juho Jalkanen. "Ralph's proven track record in biopharma leadership and his experience align perfectly with our corporate development efforts and strategic growth initiatives." Read More
(Alliance News) - Faron Pharmaceuticals Ltd on Thursday said it has raised EUR12 million from an oversubscribed placing ahead of upcoming trial results. Read More
Faron Pharmaceuticals PLC on Tuesday - Turku, Finland-based developer of cancer immunotherapies - Presents full analysis of positive phase 2 interim data from Bexmab trial at the annual meeting of the Society of Hematology in San Diego. Faron highlights an overall response rate of 80% in refractory or relapsed HMA failed MDS patient population. HMA stands for hypomethylating agents, while MDS stands for myelodysplastic syndromes. Chief Executive Officer Juho Jalkanen says: "With this compelling evidence, we are well positioned to advance to the full phase 2 efficacy readout and actively pursue further regulatory interactions to navigate and refine the pivotal pathway for BLA filing." Read More
(Alliance News) - Faron Pharmaceuticals Ltd on Wednesday reported positive data from an ongoing trial on patients receiving a new treatment for a rare blood cancer. Read More
(Alliance News) - Faron Pharmaceuticals Ltd on Tuesday said its loss widened in the first half of 2024, as the company successfully advanced the development of its flagship bexmarilimab treatment. Read More
Faron Pharmaceuticals Ltd - Turku, Finland-based clinical-stage biopharmaceutical maker - Joins consortium that has received a USD1.5 million grant from the US Department of Defense to create preservation strategies for multiple tissue types, including skin, bone, nerves and blood vessels. Tissue preservation is essential for successful transplants, due to time lags in receiving donor tissue. Faron and another industry partner, BMIOrganbank, will work with researchers at two academic centres, Duquesne University's School of Pharmacy in Pittsburg, Pennsylvania and Atrium Health Wake Forest Baptist Medical Center in Winston-Salem, North Carolina. Faron says the grant specifically will be used to investigate the use of intravenous interferon beta for the prevention of ischemia-reperfusion injury in battlefield victims when using a lifesaving tourniquet for the prevention of excessive blood loss. Read More
(Alliance News) - The following is a round-up of London-listed company director and manager changes announced in August so far and not separately reported by Alliance News: Read More
Faron Pharmaceuticals Oy - Turku, Finland-based clinical-stage biopharmaceutical company - Names Petri Bono as the new chief medical officer with effect from August 15. Bono has served as CMO of Terveystalo, the largest private healthcare service provider in Finland. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM on Thursday. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday. Read More
(Alliance News) - Faron Pharmaceuticals Ltd on Monday noted a positive read-out regarding the ongoing Bexmab trial on myelodysplastic syndrome, a form of cancer. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and Tuesday and not separately reported by Alliance News: Read More
(Alliance News) - Faron Pharmaceuticals Ltd on Monday said it appointed a new interim chief financial officer to replace the outgoing James O'Brien. Read More
(Alliance News) - Faron Pharmaceuticals Ltd on Monday said it will promote its chief operating officer to chief executive to replace his father, the company's founder. Read More
(Alliance News) - Faron Pharmaceuticals Ltd on Monday said it will promote its chief operating officer to chief executive to replace the company's founder. Read More